Syndicate Bio, a Nigerian biotech startup, has embarked on a groundbreaking collaboration with SOPHiA GENETICS, a leading cloud-based software company specializing in healthcare and data-driven medicine. This partnership marks a significant milestone as it introduces comprehensive genomic profiling and liquid biopsy services on an unprecedented scale across Africa.
Founded in September by Dr. Abasi Ene-Obong, the former CEO of the now-inactive Nigerian genomics firm 54gene, along with Dr. Jumi Popoola and Estelle Dogbo, Syndicate Bio is strategically aligning with various influential sectors such as government bodies, pharmaceutical corporations, academic institutions, and other pivotal players in the industry.
The aim is to enhance the role of precision medicine locally, while simultaneously compiling critical data sets that contribute to the advancement of global health and expedite the processes of drug discovery and development.
In November, Syndicate Bio announced a key alliance with the National Institute for Cancer Research and Treatment (NICRAT) to launch the Cancer Genome Nigeria project. The integration of the novel genomic profiling and liquid biopsy technologies will build upon the existing efforts of SOPHiA GENETICS, the Memorial Sloan Kettering Cancer Center (MSK), and Syndicate Bio to promote health equity worldwide.
Dr. Ene-Obong expressed the significance of this partnership, stating that integrating MSK-ACCESS® powered by SOPHiA DDM™ into their laboratory operations is a crucial step towards transforming the cancer treatment and research environment throughout Africa, starting with Nigeria.
He emphasized the transformative potential of next-generation sequencing technologies in oncology and liquid biopsy, which this collaboration facilitates. These technologies offer a chance to significantly advance oncology treatment and research on the continent.
The collaboration aims to democratize the use of precision medicine in oncology across Africa, with the ultimate goal of enhancing patient outcomes throughout the continent. Dr. Ene-Obong believes that the combination of their scientific expertise with the AI-driven technologies and data-centric solutions provided by SOPHiA GENETICS creates a unique opportunity to revolutionize the experience of cancer patients.
This transformation is envisioned through non-invasive cancer analysis, predictive genetic testing, and the implementation of effective precision medicine strategies.
